These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 21445776)

  • 21. Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2.
    Doloff JC; Chen CS; Waxman DJ
    Mol Cancer; 2014 Jun; 13():158. PubMed ID: 24965046
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transcriptional profiling provides insights into metronomic cyclophosphamide-activated, innate immune-dependent regression of brain tumor xenografts.
    Doloff JC; Waxman DJ
    BMC Cancer; 2015 May; 15():375. PubMed ID: 25952672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators.
    Wu J; Jordan M; Waxman DJ
    BMC Cancer; 2016 Aug; 16():623. PubMed ID: 27515027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical electron paramagnetic resonance (EPR) oximetry using India ink.
    Williams BB; Khan N; Zaki B; Hartford A; Ernstoff MS; Swartz HM
    Adv Exp Med Biol; 2010; 662():149-56. PubMed ID: 20204785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Surrogate MR markers of response to chemo- or radiotherapy in association with co-treatments: a retrospective analysis of multi-modal studies.
    Jordan BF; Gallez B
    Contrast Media Mol Imaging; 2010; 5(6):323-32. PubMed ID: 20648644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model.
    Jordan M; Waxman DJ
    Cancer Lett; 2016 Apr; 373(1):88-96. PubMed ID: 26655275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Scatter factor/hepatocyte growth factor gene transfer enhances glioma growth and angiogenesis in vivo.
    Laterra J; Nam M; Rosen E; Rao JS; Lamszus K; Goldberg ID; Johnston P
    Lab Invest; 1997 Apr; 76(4):565-77. PubMed ID: 9111517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors.
    Chenevert TL; Stegman LD; Taylor JM; Robertson PL; Greenberg HS; Rehemtulla A; Ross BD
    J Natl Cancer Inst; 2000 Dec; 92(24):2029-36. PubMed ID: 11121466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Growth kinetics and treatment response of the intracerebral rat 9L brain tumor model: a quantitative in vivo study using magnetic resonance imaging.
    Kim B; Chenevert TL; Ross BD
    Clin Cancer Res; 1995 Jun; 1(6):643-50. PubMed ID: 9816027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib.
    Ma J; Waxman DJ
    Mol Cancer Ther; 2008 Jan; 7(1):79-89. PubMed ID: 18202011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can chemotherapy replace radiotherapy in low-grade gliomas? Time for randomized studies.
    van den Bent MJ
    Semin Oncol; 2003 Dec; 30(6 Suppl 19):39-44. PubMed ID: 14765384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medium dose intermittent cyclophosphamide induces immunogenic cell death and cancer cell autonomous type I interferon production in glioma models.
    Du B; Waxman DJ
    Cancer Lett; 2020 Feb; 470():170-180. PubMed ID: 31765733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potentiation of cyclophosphamide chemotherapy using the anti-angiogenic drug thalidomide: importance of optimal scheduling to exploit the 'normalization' window of the tumor vasculature.
    Segers J; Di Fazio V; Ansiaux R; Martinive P; Feron O; Wallemacq P; Gallez B
    Cancer Lett; 2006 Nov; 244(1):129-35. PubMed ID: 16426744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate marker.
    Hall DE; Moffat BA; Stojanovska J; Johnson TD; Li Z; Hamstra DA; Rehemtulla A; Chenevert TL; Carter J; Pietronigro D; Ross BD
    Clin Cancer Res; 2004 Dec; 10(23):7852-9. PubMed ID: 15585617
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of experimental brain tumors with trombospondin-1 derived peptides: an in vivo imaging study.
    Bogdanov A; Marecos E; Cheng HC; Chandrasekaran L; Krutzsch HC; Roberts DD; Weissleder R
    Neoplasia; 1999 Nov; 1(5):438-45. PubMed ID: 10933059
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
    Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
    Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of controlled release of a cyclophosphamide derivative with polymers against rat gliomas.
    Judy KD; Olivi A; Buahin KG; Domb A; Epstein JI; Colvin OM; Brem H
    J Neurosurg; 1995 Mar; 82(3):481-6. PubMed ID: 7861228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metronomic treatment of malignant glioma xenografts with irinotecan (CPT-11) inhibits angiogenesis and tumor growth.
    Takano S; Kamiyama H; Mashiko R; Osuka S; Ishikawa E; Matsumura A
    J Neurooncol; 2010 Sep; 99(2):177-85. PubMed ID: 20066473
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.
    Kesari S; Schiff D; Doherty L; Gigas DC; Batchelor TT; Muzikansky A; O'Neill A; Drappatz J; Chen-Plotkin AS; Ramakrishna N; Weiss SE; Levy B; Bradshaw J; Kracher J; Laforme A; Black PM; Folkman J; Kieran M; Wen PY
    Neuro Oncol; 2007 Jul; 9(3):354-63. PubMed ID: 17452651
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic efficacy of metronomic chemotherapy with cyclophosphamide and doxorubicin on murine mammary adenocarcinomas.
    Mainetti LE; Rico MJ; Fernández-Zenobi MV; Perroud HA; Roggero EA; Rozados VR; Scharovsky OG
    Ann Oncol; 2013 Sep; 24(9):2310-6. PubMed ID: 23666914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.